B-Act, our single strain Bacillus licheniformis probiotic was put to the test to evaluate its ability to improve health and growth performance parameters under a necrotic enteritis (NE) challenge. The results showed that the B-Act treatment group performed as well as the group that received the antibiotic treatment.